LONDON (Alliance News) - Gene and cell therapy firm Oxford BioMedica PLC on Tuesday noted a drug which uses one of its products has been approved in Japan.
Oxford BioMedica is the sole manufacturer of the lentiviral vector used in Kymriah, a treatment developed from a patient's own T cells to fight cancer. Kymriah has been developed by Swiss giant Novartis AG.
The Japanese Ministry of Health, Labor, & Welfare has approved Kymriah to treat two specific types of leukaemia and lymphoma.
Oxford BioMedica shares were 1.6% higher on Tuesday at midday at 696 pence each.
Novartis N Ord (0QLR)